Premix insulin is the way forward for patients treating type 2 diabetes and controlling glucose levels

Dubai, United Arab Emirates - Tuesday, November 29th 2011 [ME NewsWire]

Novo Nordisk, a leading healthcare company and a world leader in diabetes care, is continuing to develop new strategies that aim to change the pattern of diabetes treatment management. This is done through a multi-pronged approach involving healthcare professional training, awareness campaigns, patient education and training of other medical personnel involved in the diabetes management.

This year at the Premix Summit on the 24th of November, Novo Nordisk highlighted the importance of insulin treatment in relation to management of diabetes. Premix insulin is an extremely effective way to be able to control patients’ sugar levels after eating a meal. This summit brought together diabetes specialists from across Asia and Europe to focus on premix insulin initiation and intensification for optimal patient care, and to discuss the latest insights about the treatment of type 2 diabetes and use of premix insulin.

In addition, the Premix Summit highlighted the epidemics of global obesity and type 2 diabetes as well as the latest clinical data; examined the importance of postprandial glucose (PPG) control in the treatment of diabetes; and discussed the value of and barriers to early insulin initiation as well as intensification.

There are new guidelines on diabetes treatment that will be released at this year’s IDF congress to be held in Dubai in December. These guidelines are produced in order to help doctors manage diabetes in all its stages. The new guidelines will give recommendations on how to treat diabetes step-by-step.

Mads Bo Larsen, vice president, Africa, Gulf and India, Novo Nordisk, said: “There is a clear need to further educate the general public about the human, social and economic drama of diabetes and its complications. We believe that awareness combined with prevention, early detection, better disease management and education can make a significant difference, both in terms of people living longer and healthier lives and to maintain a strong workforce.”

At the Premix Summit organised by Novo Nordisk, approximately 430 diabetes specialists and doctors from more than 18 countries gathered together to discuss and review treatment guidelines and the diabetes pandemic, both regionally and a on a global scale. They heard case studies and best practice presentations by specialists from both Europe and Asia.

About Novo Nordisk

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 30,100 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit www.novonordisk.com.

Contacts

To arrange interviews and/ or for further information, kindly contact:

Kiran Makhija / Sophie Wood

Tel: +971 4455 6155/ +971 44556152

Kiran.makhija@eurorscgme.com/ sophie.wood@eurorscgme.com



NovoNordisk Gulf

Tel: +966 50 444 8125

wabd@novonordisk.com